Table 2.
|
Hemodialysis,
n
=12,159 |
Peritoneal dialysis,
n
= 913 |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Medication | All | Black | White | Other | Hispanic | All | Black | White | Other | Hispanic |
n |
|
4543 |
7075 |
541 |
679 |
|
256 |
607 |
50 |
33 |
None |
12 |
10 |
13 |
13 |
11 |
10 |
8 |
10 |
xx |
xx |
Beta-blocker |
|
|
|
|
|
|
|
|
|
|
Any |
59 |
60 |
59 |
58 |
55 |
55 |
54 |
55 |
56 |
42 |
Alpha-beta |
19 |
20 |
18 |
16 |
14 |
13 |
14 |
13 |
xx |
xx |
Beta not alpha |
41 |
40 |
41 |
42 |
41 |
42 |
40 |
42 |
44 |
30 |
RAS* |
|
|
|
|
|
|
|
|
|
|
Any |
45 |
49 |
43 |
48 |
51 |
52 |
52 |
53 |
38 |
48 |
ACEI |
32 |
36 |
29 |
33 |
39 |
33 |
32 |
34 |
20 |
xx |
ARB |
17 |
18 |
17 |
18 |
16 |
23 |
23 |
22 |
26 |
xx |
CCB |
|
|
|
|
|
|
|
|
|
|
Any |
49 |
57 |
43 |
49 |
55 |
50 |
55 |
37 |
50 |
45 |
DHP |
40 |
48 |
34 |
43 |
48 |
40 |
48 |
35 |
48 |
39 |
Non-DHP |
9 |
8 |
9 |
6 |
7 |
10 |
7 |
12 |
xx |
xx |
Diuretic† |
|
|
|
|
|
|
|
|
|
|
Any |
28 |
23 |
31 |
29 |
33 |
41 |
32 |
45 |
42 |
45 |
Loop |
26 |
21 |
29 |
26 |
32 |
38 |
31 |
42 |
36 |
42 |
Thiazide |
5 |
4 |
5 |
5 |
5 |
9 |
6 |
10 |
xx |
xx |
Alpha blocker |
7 |
7 |
7 |
4 |
5 |
10 |
10 |
10 |
xx |
xx |
Central alpha 2 agonist |
19 |
27 |
15 |
12 |
19 |
15 |
21 |
14 |
xx |
xx |
Hydralazine |
8 |
10 |
7 |
5 |
9 |
4 |
6 |
3 |
xx |
xx |
Minoxidil | 4 | 6 | 3 | 3 | 2 | 2 | 5 | 2 | xx | xx |
Note: Values are percentages except for the n row, which represents numbers of patients.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DHP, dihydropyridine; RAS, renin angiotensin system agent.
*Renin-inhibitors comprised < 1% of RAS agents from 2003–2008.
†Potassium-sparing diuretics comprised < 1% of diuretic agents from 2003–2008.
xx represents less than 10 persons per cell; these percentages have been suppressed.